I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting...

Related Keywords

South Korea ,China ,Lishui ,Zhejiang ,Guangzhou ,Guangdong ,San Diego ,California ,United States ,Wuhan ,Hubei ,Shanghai ,Wuxi ,Jiangsu ,Hong Kong ,Henan ,Maryland ,Hangzhou ,Beijing ,American ,Chinese ,Gigi Feng ,Andrew Zhu ,Richard Yeh ,Genexine Neoimmunetech ,Jingwu Zang ,Corporate Development ,Holding Foreign Companies Accountable ,Company Responses To Recent ,Company American Depositary ,Holding Foreign Companies Accountable Act ,Pipeline Development ,European Society For Medical Oncology ,Us Public Company Accounting Oversight Board ,Henan Charity ,Women Leadership Council ,Research Development Expenses ,Tracon Pharmaceuticals ,Exchange Rate Information ,Morgan Stanley Capital International ,Twitter ,American Society Of Clinical Oncology ,Nasdaq ,Exchange Commission ,Prnewswire The Company Nasdaq ,Pipeline Development Highlights ,Upcoming Milestones ,Medical Oncology ,Drug Evaluation ,Clinical Oncology ,Wuxi Diagnostics ,Drug Designation ,Recent Challenges ,Cash Burn Rate ,Potential Challenges ,Company Accounting Oversight Board ,Commission Identified Issuer ,Strong Commitment ,Henan Charity General Federation ,Henan Province ,Leadership Council ,Asia Pacific Diversity ,Inclusivity Best Practice Guide ,American Depositary Shares ,I Mab Hangzhou ,Securities Litigation Reform Act ,Federal Reserve ,Operating Officer ,Chief Financial ,Comprehensive Income ,Ended December ,I Mab ,